Traws Pharma (TRAW) Competitors $1.69 -0.11 (-6.11%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$1.70 +0.02 (+0.89%) As of 06/13/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock TRAW vs. AKTX, MRSN, AADI, BDRX, KRON, ATHE, QNTM, LIAN, ITRM, and IMNNShould you be buying Traws Pharma stock or one of its competitors? The main competitors of Traws Pharma include Akari Therapeutics (AKTX), Mersana Therapeutics (MRSN), Aadi Bioscience (AADI), Biodexa Pharmaceuticals (BDRX), Kronos Bio (KRON), Alterity Therapeutics (ATHE), Quantum Biopharma (QNTM), LianBio (LIAN), Iterum Therapeutics (ITRM), and Imunon (IMNN). These companies are all part of the "pharmaceutical products" industry. Traws Pharma vs. Its Competitors Akari Therapeutics Mersana Therapeutics Aadi Bioscience Biodexa Pharmaceuticals Kronos Bio Alterity Therapeutics Quantum Biopharma LianBio Iterum Therapeutics Imunon Akari Therapeutics (NASDAQ:AKTX) and Traws Pharma (NASDAQ:TRAW) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, profitability, earnings, community ranking, dividends, valuation, media sentiment, analyst recommendations and institutional ownership. Does the MarketBeat Community believe in AKTX or TRAW? Akari Therapeutics received 262 more outperform votes than Traws Pharma when rated by MarketBeat users. CompanyUnderperformOutperformAkari TherapeuticsOutperform Votes26249.53% Underperform Votes26750.47% Traws PharmaN/AN/A Do institutionals and insiders hold more shares of AKTX or TRAW? 5.1% of Akari Therapeutics shares are held by institutional investors. Comparatively, 7.9% of Traws Pharma shares are held by institutional investors. 38.9% of Akari Therapeutics shares are held by company insiders. Comparatively, 13.6% of Traws Pharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Does the media prefer AKTX or TRAW? In the previous week, Traws Pharma had 1 more articles in the media than Akari Therapeutics. MarketBeat recorded 2 mentions for Traws Pharma and 1 mentions for Akari Therapeutics. Akari Therapeutics' average media sentiment score of 1.87 beat Traws Pharma's score of 0.44 indicating that Akari Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Akari Therapeutics Very Positive Traws Pharma Neutral Which has better valuation & earnings, AKTX or TRAW? Akari Therapeutics has higher earnings, but lower revenue than Traws Pharma. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAkari TherapeuticsN/AN/A-$10.01MN/AN/ATraws Pharma$227K41.42-$18.95M-$32.81-0.05 Which has more volatility & risk, AKTX or TRAW? Akari Therapeutics has a beta of 0.25, suggesting that its stock price is 75% less volatile than the S&P 500. Comparatively, Traws Pharma has a beta of 1.48, suggesting that its stock price is 48% more volatile than the S&P 500. Is AKTX or TRAW more profitable? Akari Therapeutics has a net margin of 0.00% compared to Traws Pharma's net margin of -62,294.25%. Company Net Margins Return on Equity Return on Assets Akari TherapeuticsN/A N/A N/A Traws Pharma -62,294.25%N/A -822.38% SummaryAkari Therapeutics beats Traws Pharma on 6 of the 10 factors compared between the two stocks. Get Traws Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for TRAW and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TRAW and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TRAW vs. The Competition Export to ExcelMetricTraws PharmaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$9.40M$6.87B$5.57B$8.50BDividend YieldN/A2.53%5.28%4.16%P/E Ratio-0.018.4326.6319.64Price / Sales41.42262.52407.99152.17Price / CashN/A65.8538.2534.64Price / Book0.136.536.964.60Net Income-$18.95M$143.25M$3.23B$248.06M7 Day Performance2.42%0.18%-1.05%-0.87%1 Month Performance36.29%11.96%8.65%3.58%1 Year PerformanceN/A3.77%33.67%14.04% Traws Pharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TRAWTraws Pharma0.6857 of 5 stars$1.69-6.1%N/AN/A$9.40M$227K-0.0117Short Interest ↑AKTXAkari TherapeuticsN/A$1.34-5.3%N/A-61.0%$43.12MN/A0.009Positive NewsMRSNMersana Therapeutics4.1129 of 5 stars$0.35-7.6%$5.20+1,405.5%-83.5%$43.05M$34.01M-0.57150AADIAadi Bioscience0.5999 of 5 stars$1.74+3.0%$1.67-4.2%+21.4%$42.97M$25.07M-0.7640BDRXBiodexa Pharmaceuticals0.4788 of 5 stars$1.16+0.9%N/AN/A$42.39M$83K0.0020Short Interest ↑KRONKronos Bio3.3182 of 5 stars$0.67+0.2%$1.63+142.5%-15.8%$40.85M$9.19M-0.47100Short Interest ↑High Trading VolumeATHEAlterity Therapeutics2.1219 of 5 stars$4.58-0.4%$12.00+162.0%+132.8%$40.61MN/A0.0010QNTMQuantum BiopharmaN/A$14.85-2.3%N/AN/A$40.18MN/A-0.96N/APositive NewsGap UpLIANLianBioN/A$0.37+2.8%N/A+12.2%$39.98MN/A-0.46110ITRMIterum Therapeutics2.423 of 5 stars$0.97+0.0%$9.00+827.8%-15.3%$38.80MN/A-0.7410Analyst RevisionGap DownIMNNImunon1.9109 of 5 stars$2.16-13.9%$15.50+617.6%+19.7%$37.89M$500K-1.1430Short Interest ↑Gap Down Related Companies and Tools Related Companies Akari Therapeutics Competitors Mersana Therapeutics Competitors Aadi Bioscience Competitors Biodexa Pharmaceuticals Competitors Kronos Bio Competitors Alterity Therapeutics Competitors Quantum Biopharma Competitors LianBio Competitors Iterum Therapeutics Competitors Imunon Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TRAW) was last updated on 6/14/2025 by MarketBeat.com Staff From Our PartnersThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredGet in stocks now - and get out on this dateGood News for Stocks 50-year Wall Street veteran, Marc Chaikin is stepping forward to share why history giv...Chaikin Analytics | Sponsored[First Look] Get in before potential 10X AI announcementsGo for 10X gains from the next big AI announcement — starting as soon as 7 days from now Former floor trade...Masters in Trading | SponsoredBig Changes Coming to Social Security?According to legendary investor Louis Navellier... This new Trump move could soon not only save Social Secu...InvestorPlace | SponsoredSHOCKING: Musk's Pentagon Secret Mission...It's about a harrowing message discovered on December 16, 2024: "美国军方暗杀名单" It's the reason President Tru...Behind the Markets | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Traws Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Traws Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
